In the nonrandomized SATIETY cohort, median 10.8-week weight gains were 8.5 kg for olanzapine, 6.1 kg for quetiapine, 5.3 kg for risperidone, 4.4 kg for aripiprazole, and 0.2 kg in 15 untreated comparison participants. Of 272 youths with postbaseline assessments, 205 completed the study.
After a median of 10.8 weeks (interquartile range, 10.5-11.2 weeks) of treatment, weight increased by 8.5 kg
In the nonrandomized SATIETY cohort, median 10.8-week weight gains were 8.5 kg for olanzapine, 6.1 kg for quetiapine, 5.3 kg for risperidone, 4.4 kg for aripiprazole, and 0.2 kg in 15 untreated comparison participants. Of 272 youths with postbaseline assessments, 205 completed the study. The planned intervention was 12 weeks, but reported outcomes followed a median 10.8 weeks. PubMed lists an erratum in JAMA 2009;302(21):2322;